Oncologic outcomes and perioperative clinicopathologic results after robot-assisted tumor-specific mesorectal excision for rectal cancer

Seung Hyuk Baik, Namkyu Kim, Dae Ro Lim, Hyuk Hur, Byung So Min, Kang Young Lee

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Robot-assisted surgery is a new and emerging surgical procedure for rectal cancer patients. However, there is a lack of information regarding oncologic outcomes for this procedure. We aimed to evaluate oncologic and perioperative clinicopathologic outcomes of surgical resection using robotic instruments for rectal cancer. Methods: Data from rectal cancer patients (n = 370) diagnosed with stage I-IV disease sited below 15 cm from the anal verge who underwent robot-assisted tumor-specific mesorectal excision consecutively from June 2006 to December 2010 were evaluated. Clinicopathologic and follow-up data were recorded prospectively and analyzed retrospectively. Perioperative clinicopathologic outcomes, postoperative complications, 3-year overall survival rate, and 3-year disease-free survival rate were analyzed. Results: All patients underwent robot-assisted tumor-specific mesorectal excision. Of all postoperative pathologic stages, 15 (4.1 %) were stage 0 (pathologic complete remission), 126 (34.1 %) stage I, 95 (25.7 %) stage II, 118 (31.9 %) stage III, and 16 (4.3 %) stage IV. The 3-year overall survival rate was 93.1 % (pathologic complete remission = 100 %, stage I = 99.2 %, stage II = 97.1 %, stage III = 90.1 %, and stage IV = 48.4 %). The 3-year disease-free survival rate was 79.2 % (pathologic complete remission = 100 %, stage I = 93.7 %, stage II = 79.8 %, stage III = 69.6 %, and stage IV = 0.0 %). The 3-year cumulative local recurrence rate was 3.6 % (n = 10). The circumferential resection margin positive rate was 5.7 % (n = 21). Local recurrence developed in one patient and systemic recurrence developed in five patients. The total number of patients with postoperative complications was 86 (23.2 %). Conclusions: These data show the feasibility and safety of robot-assisted tumor-specific mesorectal excision for rectal cancer in terms of oncologic outcomes.

Original languageEnglish
Pages (from-to)2625-2632
Number of pages8
JournalAnnals of Surgical Oncology
Volume20
Issue number8
DOIs
Publication statusPublished - 2013 Aug 1

Fingerprint

Rectal Neoplasms
Survival Rate
Neoplasms
Recurrence
Disease-Free Survival
Robotics
Safety

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Baik, Seung Hyuk ; Kim, Namkyu ; Lim, Dae Ro ; Hur, Hyuk ; Min, Byung So ; Lee, Kang Young. / Oncologic outcomes and perioperative clinicopathologic results after robot-assisted tumor-specific mesorectal excision for rectal cancer. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 8. pp. 2625-2632.
@article{2fa476c0c6dd4c40bea73ad1de483ab0,
title = "Oncologic outcomes and perioperative clinicopathologic results after robot-assisted tumor-specific mesorectal excision for rectal cancer",
abstract = "Background: Robot-assisted surgery is a new and emerging surgical procedure for rectal cancer patients. However, there is a lack of information regarding oncologic outcomes for this procedure. We aimed to evaluate oncologic and perioperative clinicopathologic outcomes of surgical resection using robotic instruments for rectal cancer. Methods: Data from rectal cancer patients (n = 370) diagnosed with stage I-IV disease sited below 15 cm from the anal verge who underwent robot-assisted tumor-specific mesorectal excision consecutively from June 2006 to December 2010 were evaluated. Clinicopathologic and follow-up data were recorded prospectively and analyzed retrospectively. Perioperative clinicopathologic outcomes, postoperative complications, 3-year overall survival rate, and 3-year disease-free survival rate were analyzed. Results: All patients underwent robot-assisted tumor-specific mesorectal excision. Of all postoperative pathologic stages, 15 (4.1 {\%}) were stage 0 (pathologic complete remission), 126 (34.1 {\%}) stage I, 95 (25.7 {\%}) stage II, 118 (31.9 {\%}) stage III, and 16 (4.3 {\%}) stage IV. The 3-year overall survival rate was 93.1 {\%} (pathologic complete remission = 100 {\%}, stage I = 99.2 {\%}, stage II = 97.1 {\%}, stage III = 90.1 {\%}, and stage IV = 48.4 {\%}). The 3-year disease-free survival rate was 79.2 {\%} (pathologic complete remission = 100 {\%}, stage I = 93.7 {\%}, stage II = 79.8 {\%}, stage III = 69.6 {\%}, and stage IV = 0.0 {\%}). The 3-year cumulative local recurrence rate was 3.6 {\%} (n = 10). The circumferential resection margin positive rate was 5.7 {\%} (n = 21). Local recurrence developed in one patient and systemic recurrence developed in five patients. The total number of patients with postoperative complications was 86 (23.2 {\%}). Conclusions: These data show the feasibility and safety of robot-assisted tumor-specific mesorectal excision for rectal cancer in terms of oncologic outcomes.",
author = "Baik, {Seung Hyuk} and Namkyu Kim and Lim, {Dae Ro} and Hyuk Hur and Min, {Byung So} and Lee, {Kang Young}",
year = "2013",
month = "8",
day = "1",
doi = "10.1245/s10434-013-2895-8",
language = "English",
volume = "20",
pages = "2625--2632",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

Oncologic outcomes and perioperative clinicopathologic results after robot-assisted tumor-specific mesorectal excision for rectal cancer. / Baik, Seung Hyuk; Kim, Namkyu; Lim, Dae Ro; Hur, Hyuk; Min, Byung So; Lee, Kang Young.

In: Annals of Surgical Oncology, Vol. 20, No. 8, 01.08.2013, p. 2625-2632.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oncologic outcomes and perioperative clinicopathologic results after robot-assisted tumor-specific mesorectal excision for rectal cancer

AU - Baik, Seung Hyuk

AU - Kim, Namkyu

AU - Lim, Dae Ro

AU - Hur, Hyuk

AU - Min, Byung So

AU - Lee, Kang Young

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background: Robot-assisted surgery is a new and emerging surgical procedure for rectal cancer patients. However, there is a lack of information regarding oncologic outcomes for this procedure. We aimed to evaluate oncologic and perioperative clinicopathologic outcomes of surgical resection using robotic instruments for rectal cancer. Methods: Data from rectal cancer patients (n = 370) diagnosed with stage I-IV disease sited below 15 cm from the anal verge who underwent robot-assisted tumor-specific mesorectal excision consecutively from June 2006 to December 2010 were evaluated. Clinicopathologic and follow-up data were recorded prospectively and analyzed retrospectively. Perioperative clinicopathologic outcomes, postoperative complications, 3-year overall survival rate, and 3-year disease-free survival rate were analyzed. Results: All patients underwent robot-assisted tumor-specific mesorectal excision. Of all postoperative pathologic stages, 15 (4.1 %) were stage 0 (pathologic complete remission), 126 (34.1 %) stage I, 95 (25.7 %) stage II, 118 (31.9 %) stage III, and 16 (4.3 %) stage IV. The 3-year overall survival rate was 93.1 % (pathologic complete remission = 100 %, stage I = 99.2 %, stage II = 97.1 %, stage III = 90.1 %, and stage IV = 48.4 %). The 3-year disease-free survival rate was 79.2 % (pathologic complete remission = 100 %, stage I = 93.7 %, stage II = 79.8 %, stage III = 69.6 %, and stage IV = 0.0 %). The 3-year cumulative local recurrence rate was 3.6 % (n = 10). The circumferential resection margin positive rate was 5.7 % (n = 21). Local recurrence developed in one patient and systemic recurrence developed in five patients. The total number of patients with postoperative complications was 86 (23.2 %). Conclusions: These data show the feasibility and safety of robot-assisted tumor-specific mesorectal excision for rectal cancer in terms of oncologic outcomes.

AB - Background: Robot-assisted surgery is a new and emerging surgical procedure for rectal cancer patients. However, there is a lack of information regarding oncologic outcomes for this procedure. We aimed to evaluate oncologic and perioperative clinicopathologic outcomes of surgical resection using robotic instruments for rectal cancer. Methods: Data from rectal cancer patients (n = 370) diagnosed with stage I-IV disease sited below 15 cm from the anal verge who underwent robot-assisted tumor-specific mesorectal excision consecutively from June 2006 to December 2010 were evaluated. Clinicopathologic and follow-up data were recorded prospectively and analyzed retrospectively. Perioperative clinicopathologic outcomes, postoperative complications, 3-year overall survival rate, and 3-year disease-free survival rate were analyzed. Results: All patients underwent robot-assisted tumor-specific mesorectal excision. Of all postoperative pathologic stages, 15 (4.1 %) were stage 0 (pathologic complete remission), 126 (34.1 %) stage I, 95 (25.7 %) stage II, 118 (31.9 %) stage III, and 16 (4.3 %) stage IV. The 3-year overall survival rate was 93.1 % (pathologic complete remission = 100 %, stage I = 99.2 %, stage II = 97.1 %, stage III = 90.1 %, and stage IV = 48.4 %). The 3-year disease-free survival rate was 79.2 % (pathologic complete remission = 100 %, stage I = 93.7 %, stage II = 79.8 %, stage III = 69.6 %, and stage IV = 0.0 %). The 3-year cumulative local recurrence rate was 3.6 % (n = 10). The circumferential resection margin positive rate was 5.7 % (n = 21). Local recurrence developed in one patient and systemic recurrence developed in five patients. The total number of patients with postoperative complications was 86 (23.2 %). Conclusions: These data show the feasibility and safety of robot-assisted tumor-specific mesorectal excision for rectal cancer in terms of oncologic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84880288750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880288750&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-2895-8

DO - 10.1245/s10434-013-2895-8

M3 - Article

VL - 20

SP - 2625

EP - 2632

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -